Skip to main content

Table 2 Trial dose specification

From: Lungtech, a phase II EORTC trial of SBRT for centrally located lung tumours – a clinical physics perspective

 

Ideal solution 8 × 7.5 Gy

Reduced prescription to meet OARs constraints 8 × 7 Gy

Underdosed PTV to meet OARs constraints 8 × 7.5 Gy

Volume

99 %

95 %

99 %

95 %

99 %

95 %

PTV

≥54 Gy (90 %)

≥60 Gy (100 %)

≥50.4 Gy (90 %)

≥56 Gy (100 %)

NA

≥48 Gy (80 %)

CTV

NA

NA

≥54 Gy (90 %) ≥60 Gy (100 %)

GTV

NA

NA

Acceptable variation

66–78Gy (110–130 %)